Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr2.71 DKK
Change Today +0.03 / 1.12%
Volume 498.0K
BIOPOR On Other Exchanges
As of 7:41 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

bioporto a/s (BIOPOR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/15 - kr3.24
52 Week Low
10/16/14 - kr1.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOPORTO A/S (BIOPOR)

Related News

No related news articles were found.

bioporto a/s (BIOPOR) Related Businessweek News

No Related Businessweek News Found

bioporto a/s (BIOPOR) Details

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings in Denmark and internationally. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric immunoassay for the determination of NGAL in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for various animal models used for drug discovery purposes, as well as for human use; and mannose-binding lectin (MBL) ELISA kit, which is based on MBL antibodies to measure MBL levels. It also provides monoclonal antibodies under the AntibodyShop name that cover various research areas, such as microbiology, biomarkers, peptide hormones, and plasma proteins. In addition, the company offers matched antibody pairs, which include capture and detection antibodies that allow users to create their customized immunoassay solutions; matched reagent sets; human monoclonal IgE antigens for use in the field of allergy research and diagnostic kit manufacturing; and controls and calibrators, as well as human serum. BioPorto A/S was founded in 2000 and is based in Hellerup, Denmark.

24 Employees
Last Reported Date: 08/7/15
Founded in 2000

bioporto a/s (BIOPOR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioporto a/s (BIOPOR) Key Developments

BioPorto A/S Reports Consolidated Earnings Results for the Second Quarter and Six Months of 2015; Revises Earnings Guidance for the Year 2015

BioPorto A/S reported consolidated earnings results for the second quarter and six months of 2015. For the quarter, the company reported net revenues of DKK 5,804,000 against DKK 4,485,000 a year ago. Loss before interest and taxes was DKK 4,038,000 against DKK 5,682,000 a year ago. Loss before taxes was DKK 4,036,000 against DKK 5,698,000 a year ago. Net loss was DKK 3,271,000 against DKK 4,645,000 a year ago. Loss per share was DKK 0.03 against DKK 0.04 a year ago. For the six months, the company reported net revenues of DKK 9,933,000 against DKK 9,236,000 a year ago. Loss before interest and taxes was DKK 8,465,000 against DKK 9,306,000 a year ago. Loss before taxes was DKK 8,523,000 against DKK 9,310,000 a year ago. Net loss was DKK 7,168,000 against DKK 8,257,000 a year ago. Loss per share was DKK 0.06 against DKK 0.07 a year ago. Cash used in operating activities was DKK 7,234,000 against DKK 9,433,000 a year ago. Purchase of intangible assets was DKK 180,000 against DKK 265,000 a year ago. Purchase of tangible assets was DKK 50,000 against DKK 542,000 a year ago. For the 2015, revenue is expected to be DKK 22-23 million in 2015, representing a growth of approximately 18% compared to 2014, against the previous guidance of DKK 22-25 million. In 2015, an EBIT of DKK 12 million and a net loss of DKK 10 million is expected, against previous guidance for LBIT level DKK 10 to 12 million and net loss of DKK 8 million to DKK 10 million.

BioPorto A/S, Q2 2015 Earnings Call, Aug 07, 2015

BioPorto A/S, Q2 2015 Earnings Call, Aug 07, 2015

BioPorto Announces Progress in Clinical Trials for the FDA Application for the NGAL l Test™ and Launch of New Generic Strip Test

BioPorto has conducted a preliminary internal assessment of the data from the completed clinical trials in the USA. These data form the basis of the registration application to the FDA for approval of The NGAL Test™. The preliminary internal assessment of data support the further application process, including the formulation of the application, which is expected to be submitted to the FDA in September 2015 at the latest. The antibody portfolio is extended with a generic strip test under the name gRAD (Generic Rapid Assay Device). gRAD is a patented lateral flow test system that allows the R&D segment to develop and apply qualitative and quantitative rapid tests for the detection of, among other, viruses and bacteria in research and veterinary use. BioPorto has in licensed the test as it is a good match for the portfolio of antibodies. The launch of the test does not affect the outlook for 2015, but is expected to become a significant product in the AntibodyShop portfolio over time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOPOR:DC kr2.71 DKK +0.03

BIOPOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr289.00 DKK -3.50
Chimerix Inc $47.54 USD -1.40
Emergent BioSolutions Inc $32.67 USD -0.62
PharmAthene Inc $1.48 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOPOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 14.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOPORTO A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at